

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-9 (Cancelled).

10. (Currently amended): An oral dosage form comprising:

(i) an erodable core which comprises [[the]] a compound, 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione or a pharmaceutically acceptable salt or [[solvate]] hydrate thereof, and another antidiabetic agent which is metformin or a pharmaceutically acceptable salt thereof,

(ii) an erodable coating around said core, which coating comprises one or more openings leading to the core, wherein the coating is erodable under predetermined pH conditions in the pH range from 4.5 to 8.

11. (Currently amended): An oral dosage form according to claim 10, wherein the coating comprises one or more openings extending substantially completely through the coating but not substantially penetrating the core and communicating from the environment of use to the core and wherein release of the compound and the other antidiabetic agent from the core occurs substantially through the one or more openings and through erosion of the coating under predetermined pH conditions.

12. (Previously presented): An oral dosage form according to claim 10, wherein the coating is an enteric coating.

13. (Previously presented): An oral dosage form according to claim 12, wherein the enteric coating is non-permeable.

14. (Previously presented): An oral dosage form according to claim 10, wherein the core is formulated to provide immediate release of both the compound and the other antidiabetic agent.

Claim 15 (Cancelled).

16. (Previously presented): An oral dosage form according to claim 10, wherein the dosage form is a tablet form.

17. (Withdrawn, currently amended): A process for the preparation of the oral dosage form according to claim 10, which process comprises:

- (a) preparing an erodable tablet core comprising the compound and another antidiabetic agent;
- (b) coating the core with a material ~~with pH dependent erodability that erodes in the pH range from 4.5 to 8~~; and
- (c) forming one or more openings in the coating.

18. (Withdrawn, previously presented): A method for the treatment of diabetes mellitus, metabolic syndrome, impaired glucose tolerance or impaired fasting glucose which method comprises administering the oral dosage form according to claim 10 to a human or non-human mammal in need thereof.